Sanofi Debt to Equity Ratio 2012-2025 | SNY
Current and historical debt to equity ratio values for Sanofi (SNY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Sanofi debt/equity for the three months ending September 30, 2025 was 0.16.
| Sanofi Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-09-30 | $65.76B | $85.95B | 0.77 |
| 2025-06-30 | $62.07B | $79.78B | 0.78 |
| 2025-03-31 | $60.55B | $78.40B | 0.77 |
| 2024-12-31 | $59.45B | $84.25B | 0.71 |
| 2024-09-30 | $0.00B | 0.00 | |
| 2024-06-30 | $61.12B | $78.61B | 0.78 |
| 2024-03-31 | $0.00B | 0.00 | |
| 2023-12-31 | $56.40B | $80.47B | 0.70 |
| 2023-09-30 | $0.00B | 0.00 | |
| 2023-06-30 | $57.14B | $79.54B | 0.72 |
| 2023-03-31 | $0.00B | 0.00 | |
| 2022-12-31 | $54.33B | $79.18B | 0.69 |
| 2022-09-30 | $0.00B | 0.00 | |
| 2022-06-30 | $53.77B | $75.88B | 0.71 |
| 2022-03-31 | $0.00B | 0.00 | |
| 2021-09-30 | $0.00B | 0.00 | |
| 2021-06-30 | $58.99B | $76.35B | 0.77 |
| 2021-03-31 | $0.00B | 0.00 | |
| 2020-09-30 | $0.00B | 0.00 | |
| 2020-03-31 | $0.00B | 0.00 | |
| 2019-09-30 | $0.00B | 0.00 | |
| 2019-03-31 | $0.00B | 0.00 | |
| 2018-03-31 | $0.00B | 0.00 | |
| 2017-12-31 | $46.98B | $65.85B | 0.71 |
| 2017-09-30 | $0.00B | 0.00 | |
| 2017-06-30 | $48.50B | $63.58B | 0.76 |
| 2017-03-31 | $0.00B | 0.00 | |
| 2016-12-31 | $51.95B | $63.88B | 0.81 |
| 2016-09-30 | $0.00B | 0.00 | |
| 2016-06-30 | $50.57B | $61.39B | 0.82 |
| 2016-03-31 | $0.00B | 0.00 | |
| 2015-09-30 | $0.00B | 0.00 | |
| 2015-06-30 | $45.52B | $62.80B | 0.73 |
| 2014-06-30 | $53.44B | $71.01B | 0.75 |
| 2013-06-30 | $53.27B | $73.39B | 0.73 |
| 2012-06-30 | $58.33B | $72.42B | 0.81 |
| 2012-03-31 | $0.00B | $0.00B | 0.00 |
| 2011-12-31 | $60.97B | $78.54B | 0.78 |
| 2011-09-30 | $0.00B | 0.00 | |
| 2011-06-30 | $67.62B | $75.69B | 0.89 |
| 2011-03-31 | $0.00B | 0.00 | |
| 2010-12-31 | $42.46B | $70.76B | 0.60 |
| 2010-09-30 | $0.00B | 0.00 | |
| 2010-06-30 | $42.97B | $67.09B | 0.64 |
| 2010-03-31 | $0.00B | 0.00 | |
| 2009-12-31 | $44.07B | $67.56B | 0.65 |
| 2009-09-30 | $0.00B | 0.00 | |
| 2009-06-30 | $43.55B | $61.00B | 0.71 |
| 2009-03-31 | $0.00B | 0.00 | |
| 2008-12-31 | $39.60B | $66.31B | 0.60 |
| 2008-09-30 | $0.00B | 0.00 | |
| 2008-06-30 | $40.71B | $64.83B | 0.63 |
| 2008-03-31 | $0.00B | 0.00 | |
| 2007-12-31 | $37.28B | $61.30B | 0.61 |
| 2007-09-30 | $0.00B | 0.00 | |
| 2007-06-30 | $39.05B | $62.17B | 0.63 |
| 2007-03-31 | $0.00B | 0.00 | |
| 2006-12-31 | $40.13B | $57.56B | 0.70 |
| 2006-09-30 | $0.00B | 0.00 | |
| 2006-06-30 | $45.74B | $56.70B | 0.81 |
| 2006-03-31 | $0.00B | 0.00 | |
| 2005-12-31 | $49.61B | $58.32B | 0.85 |
| 2005-09-30 | $0.00B | 0.00 | |
| 2005-06-30 | $56.35B | $56.24B | 1.00 |
| 2005-03-31 | $0.00B | 0.00 | |
| 2004-12-31 | $50.76B | $44.72B | 1.14 |
| 2004-06-30 | $4.49B | $8.24B | 0.55 |
| 2003-12-31 | $4.32B | $7.97B | 0.54 |
| 2003-06-30 | $3.69B | $6.36B | 0.58 |
| 2002-12-31 | $3.59B | $6.33B | 0.57 |
| 2002-06-30 | $3.24B | $5.43B | 0.60 |
| 2001-12-31 | $3.72B | $5.11B | 0.73 |
| 2001-06-30 | $3.03B | $4.13B | 0.73 |
| 2000-12-31 | $3.31B | $4.02B | 0.82 |
| 1999-12-31 | $3.26B | $3.59B | 0.91 |
| 1998-12-31 | $4.21B | $3.25B | 1.30 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $116.097B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1021.960B | 49.16 |
| Johnson & Johnson (JNJ) | United States | $505.277B | 20.20 |
| AbbVie (ABBV) | United States | $388.895B | 23.28 |
| Roche Holding AG (RHHBY) | Switzerland | $338.913B | 0.00 |
| Novartis AG (NVS) | Switzerland | $299.584B | 15.88 |
| Merck (MRK) | United States | $271.012B | 12.62 |
| Novo Nordisk (NVO) | Denmark | $267.275B | 15.67 |
| Pfizer (PFE) | United States | $143.678B | 7.90 |
| Bayer (BAYRY) | Germany | $45.349B | 7.96 |
| Innoviva (INVA) | United States | $1.454B | 7.28 |